AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.740
+0.350 (10.32%)
Mar 9, 2026, 2:48 PM EDT - Market open
AtaiBeckley Employees
AtaiBeckley had 54 employees as of December 31, 2024. The number of employees decreased by 29 or -34.94% compared to the previous year.
Employees
54
Change (1Y)
-29
Growth (1Y)
-34.94%
Revenue / Employee
$55,889
Profits / Employee
-$2,855,407
Market Cap
1.36B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54 | -29 | -34.94% |
| Dec 31, 2023 | 83 | -50 | -37.59% |
| Dec 31, 2022 | 133 | 46 | 52.87% |
| Dec 31, 2021 | 87 | 52 | 148.57% |
| Dec 31, 2020 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Precigen | 143 |
| MoonLake Immunotherapeutics | 130 |
| DBV Technologies | 117 |
| Inventiva | 84 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
ATAI News
- 2 days ago - AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript - Seeking Alpha
- 3 days ago - AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - GlobeNewsWire
- 10 days ago - AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript - Seeking Alpha
- 11 days ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 11 days ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 17 days ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire
- 7 weeks ago - AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation - GlobeNewsWire
- 2 months ago - AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference - GlobeNewsWire